BioCentury
ARTICLE | Company News

J&J adds to lung cancer arsenal with Yuhan deal

November 9, 2018 5:53 PM UTC

Janssen Pharmaceuticals Inc. licensed non-small cell lung cancer (NSCLC) compound lazertinib from Yuhan Corp. (KSE:000100) for $50 million up front and up to $1.2 billion in development and commercial milestones, giving Johnson & Johnson (NYSE:JNJ) at least its second tyrosine kinase inhibitor (TKI) and its second compound against EGFR.

Shares in the South Korean company, which is also eligible for tiered double-digit royalties, rose W53,000 (30%) to W231,000 on Nov. 5...

BCIQ Company Profiles

Johnson & Johnson

Yuhan Corp.